On Monday, Lupin educated the bourses about the positive top-line results from its critical Phase 3 clinical preliminary to evaluate the adequacy and wellbeing of single-portion Solosec (Secnidazole) 2g oral granules in 147 female patients with trichomoniasis by its US-based auxiliary. Solosec is endorsed by USFDA to treat bacterial vaginosis (BV) in ladies.

Trichomoniasis is the most widely recognized non-viral, treatable, explicitly transmitted contamination (STI) in USA. The organization's administration said that Trichomoniasis impacts an expected three to 5,000,000 individuals in USA.

Lupin intends to present a supplemental new medication application for Solosec to USFDA for the treatment of trichomoniasis in the second 50% of 2020.

On Tuesday, the load of Lupin opens hole up at Rs 858 as against its past close of Rs 841.1 and contacted an intraday high of Rs 863.9. Nonetheless, later, it chilled off and at 11.21 am, the stock was exchanging at Rs 843.